Colorectal Cancer Coverage From Every Angle
Advertisement
Advertisement

Michael J. Overman, MD, on Colorectal Cancer and Checkpoint Inhibitors: Depth and Duration of Responses

Posted: Monday, February 11, 2019

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses the durability of disease control in patients who are off treatment and continue to have some degree of disease on imaging but seem to be stable and symptom-free.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.